SCHEMBL24257788

SCHEMBL24257788

CCOC(=O)CNC(=O)c1ncc(-c2ccc3ncccc3c2)c(C)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
EGLN1 Q9GZT9 4/20 0.41
EGLN3 Q9H6Z9 3/20 0.41
VEGFA P15692 2/20 0.41
FLT1 P17948 2/20 0.41
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALOX5 P09917 1/20 0.40
CLK1 P49759 1/20 0.39
CLK2 P49760 1/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
ALOX15 P16050 2/20 0.38
FTO Q9C0B1 1/20 0.38
ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452524 1.00 KDM4E (0.46) KDM4EEGLN1EGLN3VEGFAFLT1
SCHEMBL30452725 0.88 EGLN1 (0.50) EGLN1EGLN3VEGFAFLT1CCNC
SCHEMBL24257817 0.88 EGLN1 (0.50) EGLN1EGLN3VEGFAFLT1CCNC
SCHEMBL24257637 0.88 EGLN1 (0.50) EGLN1EGLN3VEGFAFLT1CCNC
SCHEMBL30452729 0.88 EGLN1 (0.41) KDM4EEGLN1EGLN3VEGFAFLT1
SCHEMBL24257795 0.88 EGLN1 (0.41) KDM4EEGLN1EGLN3VEGFAFLT1
SCHEMBL30452447 0.84 PPID (0.42) EGLN1EGLN3VEGFAFLT1CCNC
SCHEMBL24257789 0.84 PPID (0.42) EGLN1EGLN3VEGFAFLT1CCNC
SCHEMBL24257545 0.83 ALDH1A1 (0.46) KDM4EEGLN1EGLN3VEGFAFLT1
SCHEMBL30452553 0.83 ALDH1A1 (0.46) KDM4EEGLN1EGLN3VEGFAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 KDM4E 175/4885EGLN1 19/4885EGLN3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.